Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma

Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma

<p>TILs do not respond to N-class I-peptides. TILs were stimulated with 5- or 10 μM N-class I-peptides for 5 days. 5 replicate wells were tested for proliferation, and proliferation was measured by 3H-thymidine incorporation assay. The proliferation strength is depicted as SI. (#) indicates th...

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Jian Wang (15048011) (author)
Drugi avtorji:	Tobias Weiss (15048014) (author), Marian C. Neidert (15048017) (author), Nora C. Toussaint (15048020) (author), Reza Naghavian (15048023) (author), Carla Sellés Moreno (15048026) (author), Magdalena Foege (15048029) (author), Paula Tomas Ojer (15048032) (author), Gioele Medici (15048035) (author), Ivan Jelcic (15048038) (author), Daniel Schulz (15048041) (author), Elisabeth Rushing (15048044) (author), Susanne Dettwiler (15048047) (author), Barbara Schrörs (15048050) (author), Joo Heon Shin (15048053) (author), Ron McKay (15048056) (author), Catherine J. Wu (14944480) (author), Andreas Lutterotti (15048059) (author), Mireia Sospedra (15048062) (author), Holger Moch (15048065) (author), Erich F. Greiner (15048068) (author), Bernd Bodenmiller (15048071) (author), Luca Regli (15048074) (author), Michael Weller (15037908) (author), Patrick Roth (15048077) (author), Roland Martin (15048080) (author)
Izdano:	2025
Teme:	Cancer Immuno-oncology Immunotherapy Cancer vaccines Combination immunotherapy
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Izdano: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Izdano: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Izdano: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Izdano: (2025)

Table S1 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8<sup>+</sup> T Cells
od: Snehanshu Chowdhury (14957031)
Izdano: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Izdano: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Izdano: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Izdano: (2025)

Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
od: Hiroshi Kagamu (14961732)
Izdano: (2025)

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S5 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S7 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S8 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
od: Ankita Mitra (17141783)
Izdano: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
od: Andrew Nguyen (17142197)
Izdano: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
od: Ankita Mitra (17141783)
Izdano: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
od: Ankita Mitra (17141783)
Izdano: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
od: Maria Lozano-Rabella (15056515)
Izdano: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
od: Maria Lozano-Rabella (15056515)
Izdano: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
od: Maria Lozano-Rabella (15056515)
Izdano: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
od: Isha Mondal (16721699)
Izdano: (2025)

Cross sections for dissociative recombination of ArH<sup>+</sup> and NeH<sup>+</sup> calculated using MQDT
od: Åsa Larson (22660418)
Izdano: (2025)

Image 3_A comprehensive longitudinal analysis of the cellular immune response specific to the spike protein in healthcare workers vaccinated against SARS-CoV-2– ORCHESTRA Project.pdf
od: Stefano Ugel (7402733)
Izdano: (2025)

Image 2_A comprehensive longitudinal analysis of the cellular immune response specific to the spike protein in healthcare workers vaccinated against SARS-CoV-2– ORCHESTRA Project.pdf
od: Stefano Ugel (7402733)
Izdano: (2025)

Image 4_A comprehensive longitudinal analysis of the cellular immune response specific to the spike protein in healthcare workers vaccinated against SARS-CoV-2– ORCHESTRA Project.pdf
od: Stefano Ugel (7402733)
Izdano: (2025)

Image 1_A comprehensive longitudinal analysis of the cellular immune response specific to the spike protein in healthcare workers vaccinated against SARS-CoV-2– ORCHESTRA Project.pdf
od: Stefano Ugel (7402733)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3rn5f00laif4a60t95v669jiti